Finerenone

Finerenone has been studied in 135 papers since 2022: 28 trials and 23 observational studies in people, 1 in animals, 80 reviews; 120 in the past year. It is an approved medicine. The newest story, Nov 12, 2026: “Lower quality of life linked to worse heart outcomes”.

InterventionApproved 2021

135 papers study it13 more mention it126 findingsUpdated

PubChemMeSH

53 new papers in 30 daysSee all 145 papers on finerenone

At a glance

Finerenone reduces cardiorenal events in human trials involving people with type 2 diabetes and chronic kidney disease; independent labs report fewer heart failure hospitalizations. Cohort mortality associations differ; trials report increased hyperkalemia. Bayer funds papers, employs authors and sponsors trials; aging-focused trials are registered, while some trials across uses ended over a year ago without posted results.

126 findings in 58 papers from 2023 to 2026, 31 of them since April 2026

Independent labs found the same change in people. 26 independent labs in 17 countries; 74 trials, 6 about aging, 13 with no results posted.

“Finerenone increased hyperkalaemia (RR 2.03, 95% CI: 1.82-2.26)”
Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney DiseaseDiabetes, obesity & metabolism2026doi:10.1111/dom.71305

6 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 26 independent labs in 17 countries
  • 6 findings against
  • 74 trials, 6 about aging, 13 with no results posted
  • Funders: Bayer and others
  • 49 of 101 findings with company ties
  • 27 of 74 trials sponsored by its developers
  • Human trial27
  • Humans23
  • Animals1

19 studies gave finerenone to people and measured what changed.

What changedDesignPeopleSource

down: Decreases urine albumin-to-creatinine ratio37% reduction; ratio of geometric mean change 0.63 (95% CI 0.58–0.69)

up: Increases serum potassiumSequential: +0.16 mmol/L (95% CI +0.12 to +0.21); simultaneous: +0.22 mmol/L

down: Decreases estimated glomerular filtration rateSequential: −2.7 mL/min/1.73 m2 (95% CI −3.8 to −1.6); simultaneous: −1.8 (95% CI −3.3 to −0.3)

Review of trials14 days526 people pooledCKD and T2D; simultaneous initiation of finerenone and empagliflozinESC Congress 2026 abstract, Oct 26, 2026

down: Lowers the risk of composite cardiovascular eventsHR 0.86; 95% CI 0.78–0.95

down: Lowers the risk of composite kidney eventsHR 0.76; 95% CI 0.66–0.88

Review of trialsMedian follow-up 3 yearsChronic kidney disease and type 2 diabetesESC Congress 2026 abstract, Oct 26, 2026

down: Decreases cardiovascular death and total heart failure events

no change: Has no effect on adverse events leading to treatment discontinuation

TrialMedian follow-up of 2.7 [1.9, 3.0] years6,001 peopleBothHeart failure with mildly reduced or preserved ejection fraction; across baseline CKM component countsESC Congress 2026 abstract, Oct 26, 2026

up: Increases time in target systolic blood pressure range4% (95% CI 2 to 5%)

Review of trialsfirst year18,823 people pooledBothmean age 72±9 yearsOlder adults; Heart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHgESC Congress 2026 abstract, Oct 26, 2026

down: Lowers the risk of diabetic kidney diseaseFE: HR 0.84, 95% CrI 0.77–0.92

Review of trials20,521 people pooledParticipants with type 2 diabetes and CKDFrontiers in pharmacology, Sep 24, 2026

What did studies of finerenone find?

62

Studies of finerenone measured 62 outcomes, among them mortality, urine albumin-to-creatinine ratio and cardiorenal outcomes.

Mortality

downin humans2no changein humans1HR 0.55–0.91

3 studies
  1. Finerenone is linked with lower mortality in humans (HFpEF receiving SGLT2 inhibitors vs spironolactone) (5.2% vs 10.6%; HR 0.55, 95% CI 0.42-0.72; p<0.001).

    “finerenone was associated with lower hospitalization rates (29.4% vs 40.8%; HR 0.73, 95% CI 0.65-0.82; p<0.001), acute heart failure events (17.2% vs 26.4%; HR 0.67, 95% CI 0.58-0.79; p<0.001), acute kidney injury (23.0% vs 29.7%; HR 0.83, 95% CI 0.72-0.96; p=0.010), myocardial infarction (6.9% vs 10.8%; HR 0.70, 95% CI 0.55-0.90; p=0.004), emergency department visits (23.2% vs 30.7%; HR 0.83, 95% CI 0.72-0.95; p=0.007), all-cause mortality (5.2% vs 10.6%; HR 0.55, 95% CI 0.42-0.72; p<0.001)”

    HumansHFpEF receiving SGLT2 inhibitors vs spironolactone1 year

    Finerenone versus Spironolactone in SGLT2 Inhibitor-Treated Patients with HFpEF: A Propensity-Matched Analysis

    AHA Scientific Sessions 2026 abstract

  2. Finerenone was not clearly linked with mortality in humans (heart failure (HFrEF and HFpEF)) (HFrEF: p = 0.313; HFpEF: p=0.309).

    “though no significant differences were observed in overall survival (HFrEF: p = 0.313; HFpEF: p=0.309).”

    Humansheart failure (HFrEF and HFpEF)

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease

    ESC Congress 2026 abstract

  3. Finerenone decreases mortality in humans (FINE-HEART pooled analysis) (HR 0.91, 95% CI 0.84-0.99).

    “The prespecified FINE-HEART pooled analysis showed finerenone reduced all-cause mortality (HR 0.91, 95% CI 0.84-0.99)”

    ReviewFINE-HEART pooled analysis

    Finerenone: A Non-Steroidal Mineralocorticoid Receptor Antagonist and Its Emerging Role in Cardiovascular-Kidney-Metabolic Syndrome

    Journal of cardiovascular pharmacology

Urine albumin-to-creatinine ratio

downin humans3−40% lower

3 studies
  1. Finerenone decreases urine albumin-to-creatinine ratio in humans (CKD and T2D; simultaneous initiation of finerenone and empagliflozin) (37% reduction; ratio of geometric mean change 0.63 (95% CI 0.58–0.69)).

    “Between baseline and 14 days, the simultaneous initiation strategy was associated with a 37% reduction in UACR”

    Human trialCKD and T2D; simultaneous initiation of finerenone and empagliflozin14 daysn = 526

    Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY

    ESC Congress 2026 abstract

  2. Finerenone decreases urine albumin-to-creatinine ratio in humans.

    “Finerenone led to a greater reduction than with placebo in UACR and SBP from baseline to month 4 across all concomitant medication subgroups.”

    Human trialCKD and T2D; across concomitant SGLT-2i and/or GLP-1RA medication subgroups; versus placebo4 months

    A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD

    Kidney international reports

  3. Finerenone decreases urine albumin-to-creatinine ratio in humans (~40% lower).

    “Baseline UACR was higher with greater frailty, but at month 4, finerenone was associated with an approximate 40% lower in albuminuria across all subgroups, which was significant compared with placebo (P < 0.001 for all subgroups).”

    Human trialn = 12,990

    Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis

    Clinical journal of the American Society of Nephrology : CJASN

More on Urine albumin-to-creatinine ratio

Cardiorenal outcomes

upin humans1upin reviews1

2 studies
  1. Finerenone improves cardiorenal outcomes in humans (chronic kidney disease and type 2 diabetes).

    “finerenone is the only nonsteroidal MRA with evidence of cardiovascular and renal benefits in patients with CKD and T2D”

    Reviewchronic kidney disease and type 2 diabetes

    Recent evidence for reducing cardiometabolic risk in chronic kidney disease

    Postgraduate medicine

  2. Finerenone improves cardiorenal outcomes (chronic kidney disease).

    “Renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists improve cardiorenal outcomes”

    Reviewchronic kidney disease

    Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies

    Preprints.orgPreprint

Systolic blood pressure

downin humans2

2 studies
  1. Finerenone decreases systolic blood pressure in humans (CKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors) (Sequential: −3.5 mm Hg (95% CI −5.1 to −2.0); simultaneous: −3.7 mmHg).

    “Reductions in systolic blood pressure by day 30 were comparable between the sequential”

    Human trialCKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors30 days

    Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY

    ESC Congress 2026 abstract

  2. Finerenone decreases systolic blood pressure in humans.

    “Finerenone led to a greater reduction than with placebo in UACR and SBP from baseline to month 4 across all concomitant medication subgroups.”

    Human trialCKD and T2D; across concomitant SGLT-2i and/or GLP-1RA medication subgroups; versus placebo4 months

    A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD

    Kidney international reports

Serum potassium

upin humans2

2 studies
  1. Finerenone increases serum potassium in humans (CKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors) (Sequential: +0.16 mmol/L (95% CI +0.12 to +0.21); simultaneous: +0.22 mmol/L).

    “Finerenone resulted in a similar increase in serum potassium levels by day 30”

    Human trialCKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors30 days

    Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY

    ESC Congress 2026 abstract

  2. Finerenone increases serum potassium in humans (primary aldosteronism) (+0.39±0.05 mmol/L; normal concentration in 94.5% versus 61.8% at baseline).

    “The mean increase in serum potassium concentration was 0.39±0.05 mmol/L, and 94.5% of patients exhibited a normal concentration after 12 weeks of treatment”

    Human trialprimary aldosteronism20-40 mg/d12 weeks

    Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study

    Hypertension (Dallas, Tex. : 1979)

More on Serum potassium

Heart failure events

downin humans2HR 0.75

2 studies
  1. Finerenone is linked with lower heart failure events in humans (heart failure (HFrEF and HFpEF)) (HR=0.75, 95% CI: 0.67-0.85; HR=0.62, 95% CI: 0.56-0.68).

    “In the heart failure cohorts, finerenone was associated with a significant reduction in HF events compared to steroidal MRAs”

    Humansheart failure (HFrEF and HFpEF)

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease

    ESC Congress 2026 abstract

  2. Finerenone decreases heart failure events in participants with ejection fraction ≥40% (FINEARTS-HF trial).

    “reduced HF events and cardiovascular deaths in participants with HF and ejection fraction ≥40% in the FINEARTS-HF trial”

    Reviewin participants with ejection fraction ≥40% (FINEARTS-HF trial)

    Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF

    ESC heart failure

Hyperkalemia

upin humans2RR 2.03

2 studies
  1. Finerenone increases hyperkalemia in humans (RR 2.03, 95% CI 1.82–2.26).

    “Finerenone increased hyperkalaemia (RR 2.03, 95% CI: 1.82-2.26)”

    Human trial

    Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease

    Diabetes, obesity & metabolism

  2. Finerenone increases hyperkalemia in humans (Chronic kidney disease with type 2 diabetes).

    “Finerenone increased hyperkalemia without increasing acute kidney injury.”

    ReviewChronic kidney disease with type 2 diabetes

    Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

    Diabetes, obesity & metabolism

More on Hyperkalemia

Urinary albumin-to-creatinine ratio

downin humans2−34%

2 studies
  1. Finerenone decreases urinary albumin-to-creatinine ratio in humans after empagliflozin monotherapy in type 2 diabetes and chronic kidney disease (-34.0%).

    “and by 34.0% after finerenone substitution, relative to the end of empagliflozin monotherapy.”

    Human trialafter empagliflozin monotherapy in type 2 diabetes and chronic kidney diseaseurine4 weeksn = 2

    Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

    Diabetes, obesity & metabolism

  2. Finerenone is linked with lower urinary albumin-to-creatinine ratio in humans (dual and triple therapy, within-group change) (50.6% (dual-therapy); 46.9% (triple-therapy)).

    “Within-group ln(UACR) decreased in both regimens [dual-therapy (50.6%, 28.3-65.9; P < 0.001)”

    Humansdual and triple therapy, within-group changekidney6 monthsn = 83

    Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study

    Clinical therapeutics

More on Urinary albumin-to-creatinine ratio

Chronic kidney disease

downin humans2

2 studies
  1. Finerenone decreases chronic kidney disease in humans (established diabetic chronic kidney disease).

    “Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD”

    Reviewestablished diabetic chronic kidney disease

    Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions

    Kidney research and clinical practice

  2. Finerenone decreases chronic kidney disease in humans (diabetic nephropathy with an ACR >30mg/g and an eGFR >25ml/min/1.73m2).

    “Finerenon slows CKD progression and reduces cardiovascular events.”

    Reviewdiabetic nephropathy with an ACR >30mg/g and an eGFR >25ml/min/1.73m2

    Retard chronic kidney disease progression

    Deutsche medizinische Wochenschrift (1946)

More on Chronic kidney disease

Kidney and cardiovascular events

downin humans1

1 study
  1. Finerenone decreases kidney and cardiovascular events in humans (albuminuric diabetic chronic kidney disease).

    “Finerenone reduces kidney and cardiovascular events in albuminuric diabetic CKD”

    Reviewalbuminuric diabetic chronic kidney disease

    Cardiorenal Syndrome in Older Adults: Heart–Kidney Interactions, Diagnosis, and Management

    Medical sciences (Basel, Switzerland)

Total heart failure events and cardiovascular death

downin humans1

1 study
  1. Finerenone decreases total heart failure events and cardiovascular death in humans (HFmrEF/HFpEF and CKD; irrespective of baseline 5-year KFRE score).

    “Finerenone reduced the primary outcome, irrespective of baseline 5-year KFRE score analyzed as a continuous variable”

    Human trialHFmrEF/HFpEF and CKD; irrespective of baseline 5-year KFRE score

    Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

    AHA Scientific Sessions 2026 abstract

AHA PREVENT risk score progression

downin humans1

1 study
  1. Finerenone decreases AHA PREVENT risk score progression in humans (Base-model least squares mean difference −0.018 at Month 48; p<0.01; full-model reduction from Month 4, p<0.0001).

    “Finerenone significantly reduced the progression of PREVENTTM score relative to placebo at Month 48 using the base model”

    Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; base model versus placebo48 monthsn = 7,050

    Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score

    AHA Scientific Sessions 2026 abstract

More on AHA PREVENT risk score progression

Non-fatal cardiovascular events

downin humans1

1 study
  1. Finerenone decreases non-fatal cardiovascular events in humans (Base-model HRs: low tertile 0.89 (95% CI 0.60–1.32), intermediate 1.11 (0.79–1.56), high 0.85 (0.65–1.11); interaction p=0.57).

    “Finerenone demonstrated consistent CV benefit across AHA PREVENTTM-estimated risk levels.”

    Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; comparison with placebo across baseline PREVENT risk tertilesn = 7,050

    Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score

    AHA Scientific Sessions 2026 abstract

More on Non-fatal cardiovascular events

Potassium time-in-target range

upin humans1

1 study
  1. Finerenone increases potassium time-in-target range in humans (Compared with placebo; potassium target range 4.5-5.0 mmol/L) (8% (95% CI 7-9); median 38% vs. 23%).

    “Randomization to finerenone increased TIR by 8% (95% CI 7-9) compared with placebo”

    Human trialCompared with placebo; potassium target range 4.5-5.0 mmol/Lfirst year35% womensn = 18,991

    Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

    AHA Scientific Sessions 2026 abstract

More on Potassium time-in-target range

Time in target systolic blood pressure range

upin humans1

1 study
  1. Finerenone increases time in target systolic blood pressure range in humans (Heart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHg) (4% (95% CI 2 to 5%)).

    “4% (2 to 5%) with finerenone.”

    Human trialHeart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHgfirst year

    Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials

    ESC Congress 2026 abstract

More on Time in target systolic blood pressure range

All 62

What is finerenone linked with?

36

Studies link finerenone with 36 measures, most often mortality (5 studies), hyperkalemia (4) and acute kidney injury (3).

Mortality

downin humans5HR 0.37–0.62

5 studies
  1. Finerenone is linked with a lower risk of mortality in humans (chronic kidney disease) (HR = 0.38, 95% CI: 0.32-0.45, p<0.001).

    “In CKD, it significantly reduced the risk of death (HR = 0.38, 95% CI: 0.32-0.45, p<0.001)”

    Humanschronic kidney disease

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease

    ESC Congress 2026 abstract

  2. Finerenone is associated with mortality in humans (2.1 vs 4.5 events/100 person-years; incidence rate difference -2.41 (95% CI -4.38 to -0.44)).

    “finerenone initiation was associated with lower incidence rates of all-cause death (2.1 vs 4.5 events/100 person-years; incidence rate difference, -2.41; 95% CI, -4.38 to -0.44)”

    HumansType 2 diabetes and chronic kidney disease without prior heart failure or ischemic heart disease; prior first-line SGLT2 inhibitor therapy; compared with steroidal MRAs18 months

    Finerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure

    ESC heart failure

  3. Finerenone is associated with mortality in humans (HR 0.62, 95% CI 0.47-0.81).

    “finerenone use was associated with lower 1-year risks of incident HF, MACE, MAKE, and all-cause mortality compared with non-use.”

    HumansChronic kidney disease without prior heart failure; compared with finerenone non-use after propensity score matching1 year42.5% femalesn = 11,140

    Association between finerenone use and risk of new-onset heart failure in chronic kidney disease: a propensity-matched cohort study using the TriNetX network

    BMC cardiovascular disorders

  4. Finerenone is linked with a lower risk of mortality in humans (HR 0.41; 95% CI 0.21-0.80).

    “Finerenone users were associated with a lower risk of heart failure exacerbation (HR 0.51; 95% CI 0.35-0.76), all-cause mortality (HR 0.41; 95% CI 0.21-0.80)”

    Humans1 year

    Finerenone Versus Spironolactone for Cardio-Oncology Patients With Heart Failure: Comparative Outcomes from a Propensity-Matched Analysis

    The American journal of cardiology

  5. Finerenone is associated with mortality in humans (HR 0.37; 95% CI 0.25–0.55).

    “Over 1 year, finerenone use was associated with significantly lower all-cause mortality (HR 0.37; 95% CI: 0.25 to 0.55).”

    HumansChronic kidney disease and type 2 diabetes; finerenone added to SGLT2 inhibitor therapy versus SGLT2 inhibitor monotherapy1 year

    Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study

    The American journal of cardiology

Hyperkalemia

upin humans3downin humans1HR 1.35–1.47

4 studies
  1. Finerenone raises the risk of hyperkalemia in humans (CKD and T2D; irrespective of initiation strategy).

    “Rates of hyperkalemia were higher with finerenone”

    Human trialCKD and T2D; irrespective of initiation strategy180 days

    Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY

    ESC Congress 2026 abstract

  2. Finerenone is associated with hyperkalemia in humans (Patients with chronic kidney disease and type 2 diabetes; compared with nonusers) (HR 1.47, 95% CI 1.31–1.65).

    “Finerenone initiators were more likely to experience hyperkalemia (HR, 1.47; 95% CI, 1.31-1.65).”

    HumansPatients with chronic kidney disease and type 2 diabetes; compared with nonusersmale, 53%s

    Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis

    ESC Congress 2026 abstract

  3. Finerenone is linked with a lower risk of hyperkalemia in humans (CKD and non-DM patients versus steroidal MRAs).

    “a significantly reduced risk of hyperkalemia in CKD and non-DM patients”

    HumansCKD and non-DM patients versus steroidal MRAs

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiovascular, renal and metabolic disease

    Current problems in cardiology

  4. Finerenone is associated with hyperkalemia in humans (HR 1.35; 95% CI 1.11–1.69; risk-based analyses were not statistically significant).

    “Hyperkalemia occurred more often with finerenone (HR 1.35; 95% CI: 1.11 to 1.69) although risk-based analyses did not reach statistical significance.”

    HumansChronic kidney disease and type 2 diabetes; finerenone added to SGLT2 inhibitor therapy versus SGLT2 inhibitor monotherapy1 year

    Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study

    The American journal of cardiology

More on Hyperkalemia

Acute kidney injury

downin humans3HR 0.59–0.83

3 studies
  1. Finerenone is linked with a lower risk of acute kidney injury in humans (HFpEF receiving SGLT2 inhibitors vs spironolactone) (23.0% vs 29.7%; HR 0.83, 95% CI 0.72-0.96; p=0.010).

    “acute kidney injury (23.0% vs 29.7%; HR 0.83, 95% CI 0.72-0.96; p=0.010)”

    HumansHFpEF receiving SGLT2 inhibitors vs spironolactone1 year

    Finerenone versus Spironolactone in SGLT2 Inhibitor-Treated Patients with HFpEF: A Propensity-Matched Analysis

    AHA Scientific Sessions 2026 abstract

  2. Finerenone is linked with a lower risk of acute kidney injury in humans (chronic kidney disease, diabetes mellitus, and non-DM) (HR=0.59 to 0.72, p<0.001).

    “finerenone was associated with a lower risk of acute kidney injury across CKD (HR=0.59) , DM (HR=0.72) , and non-DM (HR=0.41) phenotypes (p<0.001 for all)”

    Humanschronic kidney disease, diabetes mellitus, and non-DM

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease

    ESC Congress 2026 abstract

  3. Finerenone is linked with a lower risk of acute kidney injury in humans (CKD, DM and non-DM phenotypes versus steroidal MRAs).

    “the non-steroidal MRA was associated with a lower risk of acute kidney injury (AKI) across CKD, DM, and non-DM phenotypes”

    HumansCKD, DM and non-DM phenotypes versus steroidal MRAs

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiovascular, renal and metabolic disease

    Current problems in cardiology

More on Acute kidney injury

Composite cardiovascular outcome

downin humans2HR 0.79–0.89

2 studies
  1. Finerenone lowers the risk of composite cardiovascular outcome in humans (HR = 0.86; 95% CI: 0.78–0.95).

    “The relative hazard reduction for the composite CV outcome was slightly lower within the primary data scope (HR = 0.86; 95% CI: 0.78–0.95; p = 0.0018) compared with the on-treatment data scope (HR = 0.81; 95% CI: 0.73–0.90; p = 0.0001) (shown in online suppl. Fig. S2).”

    Human trialn = 12,990

    Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis

    American journal of nephrology

  2. Finerenone lowers the risk of composite cardiovascular outcome in humans (on-treatment) (HR 0.79, 95% CI 0.70-0.88).

    “pinteraction = 0.0959; HR = 0.79; 95% CI: 0.70-0.88; pinteraction = 0.0960, respectively).”

    Human trialon-treatment

    Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis

    American journal of nephrology

  3. Finerenone is associated with composite cardiovascular outcome in humans (Patients with chronic kidney disease and type 2 diabetes; compared with nonusers) (HR 0.89, 95% CI 0.79–1.00).

    “Finerenone initiators had lower risk of the composite CV outcome (HR, 0.89; 95% CI, 0.79-1.00)”

    HumansPatients with chronic kidney disease and type 2 diabetes; compared with nonusersmale, 53%s

    Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis

    ESC Congress 2026 abstract

Heart failure

downin humans2HR 0.67

2 studies
  1. Finerenone is linked with a lower risk of heart failure in humans (HFpEF receiving SGLT2 inhibitors vs spironolactone) (17.2% vs 26.4%; HR 0.67, 95% CI 0.58-0.79; p<0.001).

    “acute heart failure events (17.2% vs 26.4%; HR 0.67, 95% CI 0.58-0.79; p<0.001)”

    HumansHFpEF receiving SGLT2 inhibitors vs spironolactone1 year

    Finerenone versus Spironolactone in SGLT2 Inhibitor-Treated Patients with HFpEF: A Propensity-Matched Analysis

    AHA Scientific Sessions 2026 abstract

  2. Finerenone lowers the risk of heart failure in individuals with HFpEF across all ages, particularly the older populations.

    “hospitalizations for heart failure were reduced with use of finerenone and also the overall decline in individuals with HFpEF across all ages”

    Reviewin individuals with HFpEF across all ages, particularly the older populations

    Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

More on Heart failure

Major adverse cardiovascular events

downin humans2HR 0.45–0.67

2 studies
  1. Finerenone is linked with a lower risk of major adverse cardiovascular events in humans (chronic kidney disease) (HR=0.45, 95% CI: 0.39-0.52, p<0.001).

    “and adapted-MACE (HR=0.45, 95% CI: 0.39-0.52, p<0.001)”

    Humanschronic kidney disease

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease

    ESC Congress 2026 abstract

  2. Finerenone is associated with major adverse cardiovascular events in humans (HR 0.67, 95% CI 0.56-0.81).

    “Finerenone use was also associated with lower risks of MACE (HR 0.67, 95% CI 0.56-0.81; P<.001)”

    HumansChronic kidney disease without prior heart failure; compared with finerenone non-use after propensity score matching1 year42.5% femalesn = 11,140

    Association between finerenone use and risk of new-onset heart failure in chronic kidney disease: a propensity-matched cohort study using the TriNetX network

    BMC cardiovascular disorders

Kidney failure

downin humans2HR 0.71

2 studies
  1. Finerenone lowers the risk of kidney failure in humans.

    “Finerenone demonstrated consistent reductions in the ≥57% and ≥40% kidney composite outcomes compared with placebo, with no heterogeneity between the frailty subgroups (P values for interaction = 0.93 and 0.76, respectively; Figure ).”

    Human trialn = 12,990

    Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis

    Clinical journal of the American Society of Nephrology : CJASN

  2. Finerenone is linked with a lower risk of kidney failure in humans (HR 0.71; 95% CI 0.54-0.93).

    “and renal failure (HR 0.71; 95% CI 0.54-0.93) compared to spironolactone over 1 year”

    Humans1 year

    Finerenone Versus Spironolactone for Cardio-Oncology Patients With Heart Failure: Comparative Outcomes from a Propensity-Matched Analysis

    The American journal of cardiology

More on Kidney failure

Cardiovascular disease

downin humans2

2 studies
  1. Finerenone lowers the risk of cardiovascular disease in humans.

    “Across the three most frail quartiles, >Q1 to ≤Q2, >Q2 to ≤Q3, and >Q3, there was a consistent lower relative risk of the CV composite outcome in people treated with finerenone versus placebo”

    Human trial

    Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis

    Clinical journal of the American Society of Nephrology : CJASN

  2. Finerenone lowers the risk of cardiovascular disease in humans (diabetic nephropathy with an ACR >30mg/g and an eGFR >25ml/min/1.73m2).

    “reduces cardiovascular events”

    Reviewdiabetic nephropathy with an ACR >30mg/g and an eGFR >25ml/min/1.73m2

    Retard chronic kidney disease progression

    Deutsche medizinische Wochenschrift (1946)

More on Cardiovascular disease

Composite kidney outcome

downin humans1HR 0.65–0.76

1 study
  1. Finerenone lowers the risk of composite kidney outcome in humans (HR = 0.76; 95% CI: 0.66–0.88).

    “The effect of finerenone versus placebo on the composite kidney outcome appeared to be greater within the on-treatment data scope, which only included events observed up to 30 days after discontinuation of study of the drug (HR = 0.68; 95% CI: 0.57–0.81; p < 0.0001), than with the primary data scope (HR = 0.76; 95% CI: 0.66–0.88; p = 0.0001”

    Human trialn = 12,990

    Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis

    American journal of nephrology

  2. Finerenone lowers the risk of composite kidney outcome in humans (on-treatment) (HR 0.65, 95% CI 0.54-0.78).

    “kidney: 1.09 vs. 1.71; CV: 2.98 vs. 3.78) as well as after discontinuation (kidney: 11.95 vs. 13.67; CV: 14.07 vs. 14.73). The effect of finerenone on composite kidney and CV outcomes appeared to be reduced after discontinuation (hazard ratio [HR] = 0.82; 95% confidence interval [CI] 0.66-1.02; HR = 0.93; 95% CI: 0.79-1.09, respectively) versus the time on-treatment (HR = 0.65; 95% CI: 0.54-0.78;”

    Human trialon-treatment

    Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis

    American journal of nephrology

Cardiovascular death and worsening heart failure events

downin humans1RR 0.66–1.07

1 study
  1. Finerenone lowers the risk of cardiovascular death and worsening heart failure events in humans (RR 0.66 [95% CI, 0.52-0.83] in class II, RR 0.91 [95% CI, 0.76-1.07] in class III, RR 1.07 [95% CI, 0.77-1.49] in class I).

    “Compared with placebo, finerenone reduced the risk of total worsening HF events and cardiovascular death, with no interaction between FI class and the effect of finerenone (class I: RR, 1.07 [95% CI, 0.77-1.49]; class II: RR, 0.66 [95% CI, 0.52-0.83]; class III: RR, 0.91 [95% CI, 0.76-1.07]; P for interaction =.77”

    Human trialn = 5,952

    Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial

    JAMA cardiology

  2. Finerenone lowers the risk of cardiovascular death and worsening heart failure events in humans (heart failure with LVEF >= 40%) (class I: RR 1.07; class II: RR 0.66; class III: RR 0.91; P for interaction = .77).

    “In FINEARTS-HF, finerenone reduced the risk of total worsening HF events and cardiovascular death, and it improved symptoms; these effects were not modified by frailty status.”

    Human trialheart failure with LVEF >= 40%once-dailyn = 5,952

    Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial

    JAMA cardiology

Composite kidney events

downin humans1HR 0.76

1 study
  1. Finerenone lowers the risk of composite kidney events in humans (HR 0.76; 95% CI 0.66–0.88).

    “finerenone reduced composite CV (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.78–0.95) and kidney outcomes (HR 0.76; 95% CI 0.66–0.88)”

    Human trialChronic kidney disease and type 2 diabetes; compared with placebo across systolic blood pressure variability quartilesMedian follow-up 3 years

    Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis

    ESC Congress 2026 abstract

Composite cardiovascular events

downin humans1HR 0.86

1 study
  1. Finerenone lowers the risk of composite cardiovascular events in humans (HR 0.86; 95% CI 0.78–0.95).

    “finerenone reduced composite CV (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.78–0.95) and kidney outcomes (HR 0.76; 95% CI 0.66–0.88)”

    Human trialChronic kidney disease and type 2 diabetes; compared with placebo across systolic blood pressure variability quartilesMedian follow-up 3 years

    Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis

    ESC Congress 2026 abstract

Diabetic kidney disease

downin humans1HR 0.84

1 study
  1. Finerenone lowers the risk of diabetic kidney disease in humans (FE: HR 0.84, 95% CrI 0.77–0.92).

    “All three active treatments significantly reduced the risk of the composite kidney outcome relative to placebo ( Table 2 ).”

    Human trialn = 20,521

    SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis

    Frontiers in pharmacology

More on Diabetic kidney disease

Cardiovascular death or incident heart failure hospitalization

downin humans1

1 study
  1. Finerenone lowers the risk of cardiovascular death or incident heart failure hospitalization in humans (patients with CKD and T2D without HF).

    “Finerenone reduced CV death or incident HF hospitalization irrespective of baseline HFpEF-ABA score category”

    Human trialpatients with CKD and T2D without HF

    The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes

    Journal of cardiac failure

Cardiovascular, kidney and mortality outcomes

downin humans1

1 study
  1. Finerenone lowers the risk of cardiovascular, kidney and mortality outcomes in women and men; no treatment heterogeneity by sex (all Pinteraction >.05).

    “Finerenone conferred consistent benefits in women and men”

    Human trialin women and men; no treatment heterogeneity by sex (all Pinteraction >.05)

    Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis

    European heart journal

All 36

Has finerenone been tested in people?

6 of 74 about aging

Yes: 28 trials and 23 observational studies in people have been published, and 61 trials are registered.

Latest change Type 1 diabetes: Phase 3 → ApprovedNov 11, 2026

Approved

  • FDA Kerendia

    Jul 9, 2021Heart Failure, Chronic Kidney Disease, end-stage kidney disease, non-fatal myocardial infarction

  • EMA Kerendia

    Feb 16, 2022Renal Insufficiency, Chronic, Heart Failure, Chronic Kidney Disease, chronic heart failure

Repurposing

All 23

Every condition in trials

  • Henoch schonlein purpura nephritis

    Phase 4Recruiting1 trial

  • Primary membranous nephropathy

    Phase 4Recruiting1 trial

  • Type 2 diabetic kidney disease

    Phase 4Recruiting1 trial

  • HFpEF - heart failure with preserved ejection fraction

    Phase 3Recruiting1 trial

  • TAVI

    Phase 3Recruiting1 trial

  • Clinical pharmacology

    Phase 1Completed1 trial

All 7

Stopped

  • NCT06818305TerminatedKidney neoplasm

    The patient enrollment rate is proceeding too slowly

Who is developing finerenone?

1 company: Bayer.

Companies
  • BayerPhase 4chronic kidney disease, type 2 diabetes

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Reviews of human studies describe improved kidney and cardiovascular outcomes with finerenone, alongside increased hyperkalemia and adverse-event discontinuation. A human preprint in heart failure with preserved ejection fraction reports fewer adverse renal outcomes but unchanged dementia or cognitive decline incidence over six months.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 11Feb 2026: 8Mar 2026: 17Apr 2026: 2May 2026: 1Jun 2026: 4Jul 2026: 5Aug 2026: 9Sep 2026: 12Oct 2026: 26Nov 2026: 25121 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Lower quality of life linked to worse heart outcomes

Across three trials, each 0.1-point lower quality-of-life score was linked to greater relative risk of cardiovascular death or heart failure hospitalization (hazard ratio…Across three trials, each 0.1-point lower quality-of-life score was linked to greater relative risk of cardiovascular death or heart failure hospitalization (hazard ratio 1.10).

Meta-analysis · 18,694 peopleInterventions

See all 145 papers on finerenone